Fecal microbiota transplant recommended for the majority of recurrent C. diff patients

21 Feb 2024
www.sciencedaily.com
Microbial therapyClinical Study
In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection. FMT therapies are not recommended as a treatment for inflammatory bowel diseases (IBD) or irritable bowel syndrome (IBS). In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection. "Using fecal microbiota transplant, we take stool from a healthy donor and transfer it to the colon of the person with recurrent C. diff, restoring balance to their gut microbiome," explains guideline author Dr. Anne Peery. "FMT is a safe and effective treatment with enough scientific evidence to offered to most patients with two or more C. diff recurrences." In the U.S., nearly half a million people each year experience C. diff. One in six of those people will deal with a C. diff recurrence within two to eight weeks. For patients with recurrent C. diff infection at a high risk of recurrence: For hospitalized patients with severe C. diff infection: FMT therapies are not recommended as a treatment for inflammatory bowel diseases (IBD) or irritable bowel syndrome (IBS). AGA encourages patients interested in FMT for conditions other than C. diff to participate in a clinical trial. Key takeaways "C. diff is debilitating. Thanks to this new American Gastroenterological Association guideline, patients will suffer for shorter periods of time and be able to get back to leading happy and healthy lives," concluded Amanda Kabage, MS, FMT researcher and FMT recipient who contributed to the development of this guideline. This guideline covers the use of conventional FMT, performed most commonly using donor stool delivered via colonoscopy, as well as recently FDA-approved therapies such as fecal microbiota live-jslm (REBYOTA) delivered via enema and fecal microbiota spores live-brpk (VOWST) delivered in an oral capsule.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.